Rate My Professor Golo Ahlenstiel

Ahlenstiel's research encompasses innate immunity, viral hepatitis, metabolic liver disease, liver cirrhosis, portal hypertension, and the immunology of liver cancer, including the epidemiology of orphaned liver diseases and phage translocation in systemic inflammation. His scholarship includes 146 articles, chapters, and other outputs, amassing over 7,000 career citations. Prominent publications are “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy” (Nature Genetics, 2009), “The role of zinc in antiviral immunity” (Advances in Nutrition, 2019), “Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa–dependent manner” (Gastroenterology, 2010), “Global multi-stakeholder endorsement of the MAFLD definition” (The Lancet Gastroenterology & Hepatology, 2022), and “Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C” (Gut, 2006). He has received the Fellow GESA (2022), WSLHD Award for Collaborative Leadership (2022), NSW Public Servant of the Year Finalist (2022), and Westmead Institute Scientific Excellence Awards (2018, 2016). Ahlenstiel contributes to the GESA Liver Faculty Executive and SPHERE TRIPLE III Executive, driving translational programs in liver disease and cancer immunotherapy.